China SXT Pharmaceuticals (SXTC) Accumulated Expenses (2018 - 2026)

China SXT Pharmaceuticals has reported Accumulated Expenses for 9 years, with the latest figure at $2.6 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 21.0% year-over-year to $2.6 million in Q1 2026; TTM through Mar 2026 was $2.6 million, a 21.0% increase from a year earlier, with the FY2026 full-year figure at $2.6 million, up 21.0% from the prior year.
• Accumulated Expenses was $2.6 million for Q1 2026 at China SXT Pharmaceuticals, down from $3.3 million in the prior quarter.
• The five-year high for Accumulated Expenses was $3.5 million in Q1 2022, with the low at $2.2 million in Q1 2025.
• Average Accumulated Expenses over 5 years is $3.0 million, with a median of $3.1 million recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: Accumulated Expenses slipped 21.59% in 2025, then grew 21.0% in 2026.
• Over 5 years, Accumulated Expenses stood at $3.3 million in 2022, then declined by 0.89% to $3.2 million in 2023, then slipped by 10.05% to $2.9 million in 2024, then advanced by 11.77% to $3.3 million in 2025, then fell by 19.59% to $2.6 million in 2026.
• The last three Accumulated Expenses figures came in at $2.6 million (Q1 2026), $3.3 million (Q3 2025), and $2.2 million (Q1 2025), per Business Quant data.